Phathom Pharmaceuticals, Inc. (PHAT) Stock Analysis and Metrics

Phathom Pharmaceuticals

NASDAQ: PHAT

$11.45 ▼ -0.15 (-1.29%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap945.22 Mn

P/E-4.55

P/S4.61

Div. Yield0.00

Total Debt (Qtr)163.68 Mn

Revenue Growth (1y) (Qtr)104.43

Add ratio to table…

About

Phathom Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. The company’s lead products are VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK, which contain vonoprazan, a potassium competitive acid blocker that suppresses gastric acid secretion without requiring acid mediated activation. Vonoprazan is the first and only drug of its class approved for marketing and sale in the United States, providing a differentiated mechanism compared to traditional proton pump inhibitors. Phathom Pharmaceuticals, Inc. holds exclusive U. S., European and Canadian rights to vonoprazan from Takeda Pharmaceutical Company Limited and is independently commercializing its products in the United States. In addition to its commercial focus, the company is evaluating life cycle opportunities for vonoprazan, including a Phase 2 trial for eosinophilic esophagitis and potential formulations for over the counter use.

The company generates revenue solely from the sale of its three FDA approved products in the United States: VOQUEZNA tablets for erosive and non erosive gastroesophageal reflux disease, and VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK for Helicobacter pylori infection. Sales are made to pharmaceutical wholesale distributors and retail pharmacies, which then distribute the medicines to patients and healthcare providers. In 2025 the majority of revenue came from VOQUEZNA, reflecting continued growth in prescription volume and prescriber adoption since the product launch in late 2023. As of February 13, 2026, over 1.1 million prescriptions for VOQUEZNA, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK have been filled since launch. The company also reports broad commercial payer coverage, with access for over 120 million covered lives, representing more than 80% of the U. S. commercially insured population.

Phathom Pharmaceuticals, Inc. occupies a niche position as the sole provider of a potassium competitive acid blocker in the U. S. market, distinguishing itself from traditional proton pump inhibitors. Its products compete with generic PPIs such as omeprazole, esomeprazole and lansoprazole, as well as with other PPIs in development and emerging PCAB compounds like tegoprazan and fexuprazan. For H. pylori therapy, VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK face competition from generic PPI based regimens and branded alternatives such as Talicia, which combines omeprazole with antibiotics. The company’s competitive advantages include the novel mechanism of vonoprazan, its rapid onset and durable acid control, and the fact that it does not require acid activation for activity. Additionally, vonoprazan benefits from ten year new chemical entity exclusivity running through May 3, 2032, following the grant of QIDP designation and the subsequent extension under the GAIN Act. Phathom Pharmaceuticals, Inc. also maintains broad payer coverage, with its therapies accessible to over 120 million covered lives, supporting its commercial reach.

The company’s customers are primarily physicians who prescribe acid suppressive therapies, including gastroenterologists and primary care doctors, and the patients receiving treatment for GERD or H. pylori infection. Products reach end users through wholesale distributors and retail pharmacies, and the company also works with third party pharmacy support service providers to facilitate patient access, prior authorization and home delivery. Phathom Pharmaceuticals, Inc. maintains a targeted national sales force of approximately 300 representatives focused on high prescribing healthcare providers to promote its products. The company does not disclose specific customer names in its filing, but notes that its therapies are covered by national and regional health plans providing access to more than 80% of commercially insured individuals in the United States. Additionally, the firm offers patient support programs that help reduce out of pocket costs and improve adherence to therapy.

Investment Thesis

▲ Bull case

PHATHOM's core growth engine remains significantly underestimated as management emphasized persistent refill rates from the 2024 patient cohort averaging six bottles per year, yet did not fully articulate how this directly fuels compounding TRx growth beyond initial NBRx conversion. The 45% NBRx market share among the top 300 gastroenterology writers, contrasted with only 20% TRx share, reveals a substantial runway where each new patient conversion has high probability of becoming a loyal refill user, creating a self-reinforcing cycle that management acknowledged but did not quantify in terms of future revenue acceleration. This depth-focused strategy, targeting high-value prescribers rather than broad market share, positions PHAT to capture disproportionate value from gastroenterology's 20 million annual PPI prescriptions, with the potential to exceed the $1 billion GI revenue target sooner than guided if conversion and retention trends sustain. The sequential 1% Q1 revenue growth, while appearing modest, was contextualized by management as typical seasonality with late March/early April showing new all-time prescription highs for covered scripts—a leading indicator management cited for Q2 acceleration that was not fully extrapolated into near-term upside potential.
A critical unspoken catalyst lies in the Phase II Eosinophilic Esophagitis (EoE) trial, where management disclosed enrollment is ahead of schedule with topline data expected late Q4 2026 or early Q1 2027, but did not emphasize the strategic implication of acid suppression as a first-line EoE therapy. Unlike current standards requiring immunomodulators like Dupilumab, VOQUEZNA's mechanism offers a safer, well-tolerated profile with significant physician interest noted in trial sites, suggesting a potential label expansion that could unlock a new patient population beyond GERD. Management discussed the trial's progress clinically but avoided framing it as a near-term revenue diversifier, leaving the market to overlook how EoE approval could accelerate the path to profitability by adding a high-unmet-need indication with premium pricing potential, especially given the observed physician enthusiasm for enrolling patients in a trial avoiding significant immunologic burden.
The cash pay option for Medicare patients, introduced in April 2025, was mentioned as a driver of higher total prescription growth (115% YoY) versus covered prescriptions (91% YoY), yet management did not highlight its role in de-risking revenue from payer volatility or expanding addressable market among dual-eligible seniors. This channel mix shift, which contributed to the gross to net discount landing at the lower end of the 55%-59% range due to cash scripts having no rebates, actually strengthens PHAT's pricing power and reduces reliance on complex payer negotiations—a structural advantage management acknowledged only in passing when explaining Q1 gross to net performance. By not promoting this as a deliberate strategy to mitigate future payer pressure, especially with a potential second P-CAB entrant looming in 2027, the market misses how this flexibility enhances resilience and supports sustained gross margin guidance of 80% despite channel shifts.
Persistent physician advocacy, driven by tangible patient feedback described in market research (e.g., 'Doc, I've not felt this good in years'), was noted as a growth driver but not linked to organic expansion into primary care through patient-led referrals. Management described the anecdotal pattern where patients successfully treated by gastroenterologists return to their PCPs and request VOQUEZNA, creating a natural education pathway for primary care adoption—a low-cost, high-credibility channel that requires minimal sales force investment. This viral adoption loop, where validated patient outcomes fuel cross-specialty demand, was discussed as a future opportunity but not positioned as an imminent catalyst, causing the market to underestimate how primary care penetration could begin contributing to TRx growth well before the formal 2026-2027 expansion timeline suggested in prepared remarks.

PHATHOM's core growth engine remains significantly underestimated as management emphasized persistent refill rates from the 2024 patient cohort averaging six bottles per year, yet did not fully articulate how this directly fuels compounding TRx growth beyond initial NBRx conversion. The 45% NBRx market share among the top 300 gastroenterology writers, contrasted with only 20% TRx share, reveals a substantial runway where each new patient conversion has high probability of becoming a loyal refill user, creating a self-reinforcing cycle that management acknowledged but did not quantify in terms of future revenue acceleration. This depth-focused strategy, targeting high-value prescribers rather than broad market share, positions PHAT to capture disproportionate value from gastroenterology's 20 million annual PPI prescriptions, with the potential to exceed the $1 billion GI revenue target sooner than guided if conversion and retention trends sustain. The sequential 1% Q1 revenue growth, while appearing modest, was contextualized by management as typical seasonality with late March/early April showing new all-time prescription highs for covered scripts—a leading indicator management cited for Q2 acceleration that was not fully extrapolated into near-term upside potential.
A critical unspoken catalyst lies in the Phase II Eosinophilic Esophagitis (EoE) trial, where management disclosed enrollment is ahead of schedule with topline data expected late Q4 2026 or early Q1 2027, but did not emphasize the strategic implication of acid suppression as a first-line EoE therapy. Unlike current standards requiring immunomodulators like Dupilumab, VOQUEZNA's mechanism offers a safer, well-tolerated profile with significant physician interest noted in trial sites, suggesting a potential label expansion that could unlock a new patient population beyond GERD. Management discussed the trial's progress clinically but avoided framing it as a near-term revenue diversifier, leaving the market to overlook how EoE approval could accelerate the path to profitability by adding a high-unmet-need indication with premium pricing potential, especially given the observed physician enthusiasm for enrolling patients in a trial avoiding significant immunologic burden.
The cash pay option for Medicare patients, introduced in April 2025, was mentioned as a driver of higher total prescription growth (115% YoY) versus covered prescriptions (91% YoY), yet management did not highlight its role in de-risking revenue from payer volatility or expanding addressable market among dual-eligible seniors. This channel mix shift, which contributed to the gross to net discount landing at the lower end of the 55%-59% range due to cash scripts having no rebates, actually strengthens PHAT's pricing power and reduces reliance on complex payer negotiations—a structural advantage management acknowledged only in passing when explaining Q1 gross to net performance. By not promoting this as a deliberate strategy to mitigate future payer pressure, especially with a potential second P-CAB entrant looming in 2027, the market misses how this flexibility enhances resilience and supports sustained gross margin guidance of 80% despite channel shifts.
Persistent physician advocacy, driven by tangible patient feedback described in market research (e.g., 'Doc, I've not felt this good in years'), was noted as a growth driver but not linked to organic expansion into primary care through patient-led referrals. Management described the anecdotal pattern where patients successfully treated by gastroenterologists return to their PCPs and request VOQUEZNA, creating a natural education pathway for primary care adoption—a low-cost, high-credibility channel that requires minimal sales force investment. This viral adoption loop, where validated patient outcomes fuel cross-specialty demand, was discussed as a future opportunity but not positioned as an imminent catalyst, causing the market to underestimate how primary care penetration could begin contributing to TRx growth well before the formal 2026-2027 expansion timeline suggested in prepared remarks.

▼ Bear case

PHATHOM's path to operating profitability by Q3 2026 and positive cash flow in 2027 hinges on expense discipline that may be overstated, as Sanjeev Narula attributed the 43% year-over-year decrease in cash operating expenses to prior-period base effects rather than sustainable structural savings. The sequential increase in Q1 expenses to $56.2 million was driven by sales force expansion (nearly 50 new reps), the annual sales meeting, and Phase II EoE trial ramp-up—costs management framed as temporary but which represent a permanent step-up in the operating base now that the sales team exceeds 290 representatives. With cash operating expense guidance for 2026 set at $235-$255 million, the implied Q2-Q4 run rate of ~$60-$63 million per quarter leaves minimal room for error, especially if the anticipated modest Q2 step-up from the fully ramped sales force exceeds expectations due to higher-than-planned compensation, travel, or sample costs tied to depth-focused gastroenterologist calling.
The gross to net discount range of 55%-59% guidance faces upward pressure from an unfavorable channel mix shift that management acknowledged but did not fully confront, as the growing proportion of cash pay prescriptions—while beneficial for gross margin—reduces net revenue per script and increases reliance on patient affordability in an inflationary environment. Covered prescriptions grew 91% YoY but represented only 63% of Q1 fills, with the remaining 37% cash pay (including Medicare patients using the new cash option) generating no rebate revenue yet still incurring full cost of goods sold. If economic pressures cause patients to shift further toward cash pay to avoid prior authorization hassles or high deductibles, the gross to net discount could creep toward the top end of the guidance range, directly compressing net revenue growth despite strong TRx trends—a risk management deflected by noting quarterly variability without addressing whether the current mix represents a new normal.
VOQUEZNA's competitive moat against a potential second P-CAB entrant (Tegoprazan) in 2027 is weaker than management implied, as their reliance on physician habit formation and first-mover advantages overlooks the likelihood of aggressive payer steering and formulary positioning by the new competitor. While Steven Basta emphasized VOQUEZNA's 93% healing rate in Phase III EE trials versus Tegoprazan's 85%, he admitted cross-trial comparisons have limitations and failed to address how payers might favor the entrant with lower net cost after rebates, especially if Tegoprazan's manufacturer offers aggressive contracting to gain market share. The assertion that 'there's just no compelling reason to switch' ignores real-world dynamics where payers, not physicians, often dictate formulary placement, and a second entrant could trigger RFPs that disadvantage VOQUEZNA despite superior clinical data—a nuance absent from management's confident dismissal of competitive threats.
Persistent refill data showing an average of six bottles per year for 2024 starters may overstate durability, as management conceded the analysis likely understates discontinuation due to 18% of apparent non-persisters restarting therapy within 12 months—a pattern suggesting unstable adherence driven by episodic symptom relief rather than chronic disease management. This 'stop-start' behavior, where patients discontinue VOQUEZNA during symptom-free periods and restart only upon flare-ups, indicates the drug may be used more like an as-needed therapy than a daily maintenance medication, undermining the assumption that NBRx conversions reliably translate to long-term TRx revenue. If this pattern persists or worsens with broader adoption, the lifetime value per new patient could fall significantly short of models supporting the $1 billion GI revenue target, a risk management highlighted only in the context of data limitations without discussing implications for forecast sustainability.

PHATHOM's path to operating profitability by Q3 2026 and positive cash flow in 2027 hinges on expense discipline that may be overstated, as Sanjeev Narula attributed the 43% year-over-year decrease in cash operating expenses to prior-period base effects rather than sustainable structural savings. The sequential increase in Q1 expenses to $56.2 million was driven by sales force expansion (nearly 50 new reps), the annual sales meeting, and Phase II EoE trial ramp-up—costs management framed as temporary but which represent a permanent step-up in the operating base now that the sales team exceeds 290 representatives. With cash operating expense guidance for 2026 set at $235-$255 million, the implied Q2-Q4 run rate of ~$60-$63 million per quarter leaves minimal room for error, especially if the anticipated modest Q2 step-up from the fully ramped sales force exceeds expectations due to higher-than-planned compensation, travel, or sample costs tied to depth-focused gastroenterologist calling.
The gross to net discount range of 55%-59% guidance faces upward pressure from an unfavorable channel mix shift that management acknowledged but did not fully confront, as the growing proportion of cash pay prescriptions—while beneficial for gross margin—reduces net revenue per script and increases reliance on patient affordability in an inflationary environment. Covered prescriptions grew 91% YoY but represented only 63% of Q1 fills, with the remaining 37% cash pay (including Medicare patients using the new cash option) generating no rebate revenue yet still incurring full cost of goods sold. If economic pressures cause patients to shift further toward cash pay to avoid prior authorization hassles or high deductibles, the gross to net discount could creep toward the top end of the guidance range, directly compressing net revenue growth despite strong TRx trends—a risk management deflected by noting quarterly variability without addressing whether the current mix represents a new normal.
VOQUEZNA's competitive moat against a potential second P-CAB entrant (Tegoprazan) in 2027 is weaker than management implied, as their reliance on physician habit formation and first-mover advantages overlooks the likelihood of aggressive payer steering and formulary positioning by the new competitor. While Steven Basta emphasized VOQUEZNA's 93% healing rate in Phase III EE trials versus Tegoprazan's 85%, he admitted cross-trial comparisons have limitations and failed to address how payers might favor the entrant with lower net cost after rebates, especially if Tegoprazan's manufacturer offers aggressive contracting to gain market share. The assertion that 'there's just no compelling reason to switch' ignores real-world dynamics where payers, not physicians, often dictate formulary placement, and a second entrant could trigger RFPs that disadvantage VOQUEZNA despite superior clinical data—a nuance absent from management's confident dismissal of competitive threats.
Persistent refill data showing an average of six bottles per year for 2024 starters may overstate durability, as management conceded the analysis likely understates discontinuation due to 18% of apparent non-persisters restarting therapy within 12 months—a pattern suggesting unstable adherence driven by episodic symptom relief rather than chronic disease management. This 'stop-start' behavior, where patients discontinue VOQUEZNA during symptom-free periods and restart only upon flare-ups, indicates the drug may be used more like an as-needed therapy than a daily maintenance medication, undermining the assumption that NBRx conversions reliably translate to long-term TRx revenue. If this pattern persists or worsens with broader adoption, the lifetime value per new patient could fall significantly short of models supporting the $1 billion GI revenue target, a risk management highlighted only in the context of data limitations without discussing implications for forecast sustainability.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password